Related Experiment Video
Updated: Jul 11, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
The effect of triptolide on apoptosis of glioblastoma multiforme (GBM) cells
1College of Life Science and Biotechnology, Jiaotong University, Shanghai, China. jianlinmt@163.com
Abstract:
Triptolide, derived from the traditional Chinese herb, Tripterygium wilfordii, sensitizes cancer cells to apoptosis. Glioblastoma multiforme (GBM), which accounts for most cases of central nervous malignancy, has a very poor prognosis and lacks effective therapeutic inventions. We, therefore, investigated the effects of different concentrations of, and different periods of exposure to, triptolide on cell proliferation and apoptosis in the glioma cell lines, U251MG and U87MG, and in normal human fetal astrocytes. Cell proliferation was investigated by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay and growth curve analysis, and apoptosis was assessed from genomic DNA fragmentation. Triptolide showed dose-dependent inhibition of cell proliferation and induction of apoptosis in glioma cells. It also increased the ratio of the pro-apoptotic protein, Bax, to the anti-apoptotic protein, Bcl-2. Since U87MG has the wild-type p53 gene whereas U251MG harbours a mutated p53 gene, our results indicate that triptolide induces apoptosis in GBM cells via a p53-independent pathway. The dose-dependent inhibition of cell proliferation and induction of apoptosis by triptolide may involve upregulation of Bax and downregulation of Bcl-2.
Insights
Triptolide, from Tripterygium wilfordii, inhibits glioma cell growth and promotes apoptosis. This natural compound shows promise for treating glioblastoma multiforme (GBM) via a p53-independent mechanism.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with limited treatment options.
- Triptolide, a compound from Tripterygium wilfordii, has shown potential in sensitizing cancer cells to apoptosis.
Purpose of the Study:
- To investigate the effects of triptolide on glioma cell proliferation and apoptosis.
- To determine the mechanism of triptolide-induced apoptosis in GBM cells, particularly its relation to p53 status.
Main Methods:
- Glioma cell lines (U251MG, U87MG) and normal astrocytes were treated with varying concentrations and durations of triptolide.
- Cell proliferation was assessed using MTT assays and growth curve analysis.
- Apoptosis was evaluated through genomic DNA fragmentation and analysis of Bax/Bcl-2 protein ratios.
Main Results:
- Triptolide demonstrated dose-dependent inhibition of glioma cell proliferation.
- Triptolide induced apoptosis in U251MG and U87MG cells.
- The ratio of pro-apoptotic Bax to anti-apoptotic Bcl-2 increased, suggesting modulation of apoptosis pathways.
- Apoptosis induction occurred independently of the p53 gene status in the tested glioma cells.
Conclusions:
- Triptolide effectively inhibits glioma cell proliferation and induces apoptosis in a dose-dependent manner.
- The findings suggest triptolide may represent a novel therapeutic strategy for GBM.
- Triptolide-induced apoptosis in GBM cells operates through a p53-independent pathway, potentially involving Bax/Bcl-2 modulation.
